Benzonitrate-containing heterocyclic derivative regulator, method for preparing the same, and use thereof

Abstract

Benzonitrate-containing heterocyclic derivative modifiers, methods for preparing the same, and uses thereof. In particular, the present invention relates to a compound represented by general formula (XIX), a method for preparing the same, a pharmaceutical composition containing the compound, and the use of the compound as a modifier in the preparation of pharmaceuticals for the treatment of metabolic diseases and related diseases, wherein each substituent in general formula (XIX) is as defined herein. [Case 1] TIFF0007898037000624.tif49131

Description

[Technical Field]

[0001] This invention belongs to the fields of medicine and biology, and more specifically, to a benzene nitrogen-containing heterocyclic derivative regulator, as well as a method for preparing the same and its applications. [Background technology]

[0002] Diabetes mellitus is a common endocrine and metabolic disorder. It is caused by metabolic disorders resulting from various factors, leading to damage to many systems and organs. Its prevalence is high. There are approximately 425 million people with diabetes worldwide. In China, the prevalence of diabetes is about 10%, with type 2 diabetes accounting for 90% of these cases. The prevalence continues to increase, and the age of patients is getting younger.

[0003] Currently, many types of medications are available on the market to treat type 2 diabetes. These include insulin, biguanides, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and alpha-glucosidase inhibitors. Of these, GLP-1 receptor agonists are the most widely used.

[0004] GLP-1 is a peptide hormone secreted by human intestinal L cells. Its receptors are distributed in pancreatic islet cells, various gastrointestinal cells, and neurons in the central and peripheral nervous systems. After activation of the GLP-1 receptor, it exerts physiological effects such as promoting insulin secretion, suppressing glucagon secretion, suppressing appetite, and delaying gastric emptying. Clinical evidence has shown that GLP-1 receptor agonists have superior blood glucose-lowering effects and a lower likelihood of causing side effects such as hypoglycemia compared to other hypoglycemic agents. Furthermore, they also have additional benefits for the cardiovascular system and can lead to reduced food intake and delayed gastric emptying, which is beneficial for weight management.

[0005] Currently, all commercially available GLP-1 receptor agonists are peptide drugs, but most of them require subcutaneous administration and have low patient compliance. On the other hand, the bioavailability of oral peptide drugs is extremely low. Therefore, the development of small molecule GLP-1 receptor agonists for oral use is strongly clinically demanded.

Summary of the Invention

Problems to be Solved by the Invention

[0006] Currently, there are no approved small molecule GLP-1 receptor agonists, and there is a great clinical need. Oral small molecule GLP-1 receptor agonists with low cost and excellent medication compliance have the potential to treat various metabolic diseases, and thus have a broad market outlook.

Means for Solving the Problems

[0007] An object of the present invention is to provide a compound represented by the general formula (XIX):

Chemical Formula

[0007] , , , ,

[0006] , , 1-6 , 1-6 , 1-6 , 1-6 , 2-6 , , 13 , 1-6 , , 1-6 , , , is hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 alkyl, C 1-6 deuterated alkyl, C 1-6 haloalkyl, C 1-6 deuterated haloalkyl, C 1-6 hydroxyalkyl, C 1-6 deuterated hydroxyalkyl, C 1-6 sulfanyl, C 1-6 deuterated sulfanyl, C 1-6 alkoxy, C 1-6 deuterated alkoxy, C 1-6 haloalkoxy, C 1-6 deuterated haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; L1, L2, or L3 are each independent, combined, C 2-4 Alkenylene, C 2-4 Alkynylene or -(CH2)n1 - Selected from; Ring A is C 3-14 Cycloalkyl, 3-14 member heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl; Ring B is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Ring C is C 3-14 Cycloalkyl, 3-14 member heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6It may be further substituted with one or more substituents selected from deuterated haloalkoxys; Ring D is C 3-12 Selected from cycloalkyl, 3- to 12-membered heterocyclyl, C 6-14 Aryl or 5- to 14-membered heteroaryl; Ring E is C 3-14 Selected from cycloalkyl, 3- to 14-membered heterocyclyl, C 6-14 Aryl or 5- to 14-membered heteroaryl, where these are deuterium, halogen, amino, nitro, hydroxy, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Selected from cycloalkyl, 3- to 8-membered heterocyclyl, C 6-10 Aryl or 5- to 10-membered heteroaryl and may be further substituted with one or more substituents; Alternatively, ring E is

Chemical formula

[0008] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R 13 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl compounds.

[0009] Preferably, R 13 is selected from -CD3, hydrogen, deuterium, fluorine, chlorine, bromine, methyl or cyclopropyl, where these are deuterium, halogen or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0010] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: Ring A is C 3-12 A 3-12 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-12Selected from aryl or 5-12 membered heteroaryls containing 1-3 atoms selected from N, O, or S; Preferably, ring A is C 6-12 Selected from cycloalkyl, 6-12 membered heterocyclic compounds containing 1-3 N, O, or S atoms, or 6-12 membered heteroaryl compounds containing 1-3 N, O, or S atoms; More preferably, ring A is [ka] Selected from.

[0011] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: Ring B is C 3-8 A 3-8 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 atoms selected from N, O, or S; these are deuterium, halogen, amino, oxo, thiol, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring B is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms; these are deuterium, halogens, amino, oxo, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; More preferably, ring B is [ka] Selected from; these are deuterium, halogen, amino, oxo, thio or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0012] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: Ring C is C 3-8 A 3-8 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-8 membered heteroaryls containing 1-3 atoms selected from N, O, or S; these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy or C 1-3 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Preferably, ring C is C 3-8 Selected from cycloalkyl, 3-8 membered heterocyclic compounds containing 1-3 atoms selected from N, O, or S, or 5-8 membered heteroaryl compounds containing 1-3 atoms selected from N, O, or S; these are deuterium, hydroxyl, thioxo, oxo, or C 1-3 They may be further substituted with one or more substituents selected from haloalkoxys; More preferably, ring C is [ka] These are selected from; these may be further substituted with one or more substituents selected from deuterium, hydroxyl, thio, or oxo.

[0013] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: Ring D is C3-8 Cycloalkyl, 3-8 membered heterocycline containing 1-3 atoms selected from N, O, or S, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 atoms selected from N, O, or S; Preferably, ring D is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclines containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms; More preferably, ring D is [ka] Selected from.

[0014] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: Ring E is C 3-8 A 3-10 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 atoms selected from N, O, or S, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, ring E is [ka] These are selected from, where they may be substituted with one or more substituents selected from methyl, ethyl, methoxy, or ethoxy.

[0015] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 14 , R 15 or R 16 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m1 Ure c1 Or (=C)R c3 R c4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -(CH2) m1 Ure c1 Or (=C)R c3 R c4 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more aryl or 5-8 member heteroaryl groups; Preferably, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 14 , R 15 or R 16These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -(CH2) m1 Ure c1 Or (=C)R c3 R c4 Selected from, where the amino acid, C 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -(CH2) m1 Ure c1 Or (=C)R c3 R c4 Deuterium, amino, halogen, deuterated methyl, hydroxyl, methyl, cyclopropyl, oxo, thio, C 1-3 Alkyl or C 1-3 They may be further substituted with one or more substituents selected from alkoxy; More preferably, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 14 , R 15 or R 16 These are, independently, hydrogen, oxo, thio, cyano, methyl, fluorine, chlorine, cyclopropyl, ethynyl, and -(CH2) m1 Ure c1 Or (=C)R c3 R c4 Selected from, where the cyclopropyl, ethynyl, -(CH2) m1 Ure c1 Or (=C)R c3 R c4 deuterium, fluorine, chlorine, bromine, hydroxyl, -CD3, methyl, ethyl, cyclopropyl, oxo, thio or [ka] It may be further substituted with one or more substituents.

[0016] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R c1 , R c3 or R c4 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more aryl or 5-8 member heteroaryl groups; Preferably, R c1 , R c3 or R c4 Fluorine, methyl, cyano, -CH2F, difluoromethyl, trifluoromethyl, ethinyl, methylthio, amino, cyclopropyl, oxetane, phenyl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2Selected from, where, amino, methyl, -CH2F, difluoromethyl, trifluoromethyl, ethinyl, methylthio, cyclopropyl, oxetane, phenyl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 It may be further substituted with one or more substituents of deuterium, halogen, methoxy, methyl deuterated, or hydroxyl.

[0017] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R a1 , R a2 , R b1 or R c2 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more aryl or 5-8 member heteroaryl groups; Preferably, R a1 , R a2 , R b1 or R c2 Each of these is independently selected from fluorine, methyl, ethyl, -CH2F, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, oxetane, or phenyl, where the amino, methyl, ethyl, -CH2F, difluoromethyl, trifluoromethyl, ethynyl, methylthio, cyclopropyl, oxetane, or phenyl may be further substituted with one or more substituents of deuterium, halogen, methoxy, deuterated methyl, or hydroxyl.

[0018] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R 9 or R 16 Each of them is bonded to the atom it is connected to and becomes C 3-6 A 3-6 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Forms a 5-8 membered heteroaryl compound containing aryl or 1-3 atoms selected from N, O, or S; Preferably, R 9 or R 16 It then bonds with the atom it is attached to to form a cyclopropyl group.

[0019] In a further preferred embodiment of the present invention, the compound represented by general formula (XIX) is as follows: R 1 and R 1 , R 2 and R 1 , R 4 and R 5 , R 5 and R 6 , R 7 and R 8 It connects with the atoms bonded to them and C 3-10 Cycloalkyl, 3-6 membered heterocyclic, C 6-12 They form aryl or 5-12 member heteroaryl compounds, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 and R 1 , R 2 and R 1 , R 4 and R 5 , R 5 and R 6 , R 7 and R 8 It binds to the atoms that are bonded to them and forms cyclopropyl, [ka] These are formed, which may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxy, cyano, oxo, thioxo, methyl, or ethyl.

[0020] The object of the present invention is the general formula (XVIII): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 14 , R 15 or R 16 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-8-(CH2) m1 Ure c1 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R a2 , R b1 or R c2 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, 3 - 8 membered heterocyclyl, C 6-10 May be further substituted with one or more substituents selected from aryl or 5 - 10 membered heteroaryl; Alternatively, R 9 Or R 16 Is linked to the atom to which it is attached to form C 3-10 Cycloalkyl, 3 - 10 membered heterocyclic, C 6-12 Aryl or 5 - 12 membered heteroaryl; R 1 And R 10 R 2 And R 12 R 4 And R 5 R 5 And R 6 R 7 And R 8 R 10 And R 12 Are linked to the atoms to which they are attached to form C 3-10 Cycloalkyl, 3 - 10 membered heterocyclyl, C 6-12 Aryl or 5 - 12 membered heteroaryl, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 13 L1, L2, L3, ring A, ring B, ring C, and ring E are as described in general formula (XIX); n1, m1, m2, m3, or m4 are each independently selected from 0, 1, 2, 3, 4, or 5.

[0021] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 14 , R 15 or R 16 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8-(CH2) m1 Ure c1 Selected from, where the amino acid, C1-3 Alkyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 membered heteroaryl or -(CH2) m1 OR c1 is deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 alkyl, C 1-3 deuterated alkyl, C 1-3 haloalkyl, C 1-3 deuterated haloalkyl, C 1-3 hydroxyalkyl, C 1-3 deuterated hydroxyalkyl, C 1-3 sulfanyl, C 1-3 deuterated sulfanyl, C 1-3 alkoxy, C 1-3 deuterated alkoxy, C 1-3 haloalkoxy, C 1-3 deuterated haloalkoxy, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl; Preferably, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8, R 9 , R 10 , R 12 , R 14 , R 15 or R 16 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Selected from, where the amino acid, C 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Deuterium, amino, halogen, deuterated methyl, hydroxyl, methyl, cyclopropyl, oxo, thio, C 1-3 Alkyl or C 1-3 They may be further substituted with one or more substituents selected from alkoxy; More preferably, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 14 , R 15 or R 16 Each of these is independently hydrogen, oxo, thio, cyano, methyl, fluorine, chlorine, cyclopropyl, ethynyl, or -(CH2) m1 Ure c1 Selected from, where the cyclopropyl, ethynyl or -(CH2) m1 Ure c1 deuterium, fluorine, chlorine, bromine, hydroxyl, -CD3, methyl, ethyl, cyclopropyl, oxo, thio or [ka] It may be further substituted with one or more substituents.

[0022] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R c1 Fluorine, methyl, cyano, -CH2F, difluoromethyl, trifluoromethyl, ethinyl, methylthio, amino, cyclopropyl, oxetane, phenyl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2Selected from, where, amino, methyl, -CH2F, difluoromethyl, trifluoromethyl, ethinyl, methylthio, cyclopropyl, oxetane, phenyl, -(CH2) m2 Ure c2 ,-(CH2) m3 C(O)NR a1 R b1 or -(CH2) m4 C(O)OR a2 It may be further substituted with one or more substituents of deuterium, halogen, methoxy, methyl deuterated, or hydroxyl.

[0023] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R a1 , R a2 , R b1 or R c2 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R a1 , R a2 , R b1 or R c2Each of these is independently selected from fluorine, methyl, ethyl, -CH2F, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, oxetane, or phenyl, where the methyl, ethyl, -CH2F, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, oxetane, or phenyl may be further substituted with one or more substituents of deuterium, halogen, methoxy, deuterated methyl, or hydroxyl.

[0024] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R 9 or R 16 Each of them is bonded to the atom it is connected to and becomes C 3-6 A 3-6 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Forms a 5-8 membered heteroaryl compound containing aryl or 1-3 atoms selected from N, O, or S; Preferably, R 9 or R 16 It then bonds with the atom it is attached to to form a cyclopropyl group.

[0025] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R 1 and R 10 , R 2 and R 12 , R 4 and R 5 , R 5 and R 6 , R 7 and R 8 , R 10 and R 12 It connects with the atoms bonded to them and C 3-6 A 3-6 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10Forms 5-8 membered heteroaryls containing aryl or 1-3 atoms selected from N, O, or S, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 and R 10 , R 2 and R 12 , R 4 and R 5 , R 5 and R 6 , R 7 and R 8 , R 10 and R 12 It binds to the atoms that are bonded to them and forms cyclopropyl, [ka] These are formed, which may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, oxo, thioxo, methyl, or ethyl.

[0026] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is as follows: R1 and R 10 , R 2 and R 12 , R 4 and R 5 , R 5 and R 6 , R 7 and R 8 , R 10 and R 12 It binds to the atoms that are bonded to them and forms cyclopropyl, [ka] These are formed, which may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxyl, cyano, oxo, thioxo, methyl, or ethyl.

[0027] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is further represented by general formula (XVIIIA): [ka] This is expressed as follows, where in the above formula, ring A, ring B, ring C, ring E, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 , R 15 , R 16 L1, L2, and L3 are defined in general formula (XVIII).

[0028] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is further represented by general formula (XVIIIB): [ka] It is expressed as, where in the above formula, R1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 14 , R 15 And L1 are as defined in general formula (XVIII).

[0029] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is further represented by general formula (XVIII-1): [ka] It is represented as follows.

[0030] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is further represented by general formula (XVIII-A-1): [ka] It is represented as follows.

[0031] In a further preferred embodiment of the present invention, the compound represented by general formula (XVIII) is further represented by general formula (XVIII-B-1): [ka] It is represented as follows.

[0032] The object of the present invention is the general formula (V): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, R 4 , R 5 or R 6These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryls and 5-10 member heteroaryls; Alternatively, R 5 and R 6 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents of an aryl or 5-10 member heteroaryl; R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n2 R a5 R b5 or [ka] Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxy, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R b5 , R a6 or R b6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryls and 5-10 membered heteroaryls; Alternatively, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a5 and R b5 , R a6 and R b6 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents of an aryl or 5-10 member heteroaryl; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxy, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10Aryl or 5-10 member heteroaryls include halogens, aminos, nitros, hydroxys, cyanos, oxos, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -(CH2) n2 R a5 R b5 or [ka] Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8C 6-10They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 to n3 are integers from 0 to 5; m1 is an integer between 0 and 5; Here, R 7 and R 8 is hydrogen, R 9 , R 10 and R 12 is methyl, and also, R 3 and R 5 If R is fluorine, 4 and R 6 It cannot be methyl at the same time; R 7 and R 8 is hydrogen, R 9 , R 10 and R 12 is methyl, R 3 is hydrogen, and also, R 5 If there is a halogen, R 4 and R 6 It cannot be methyl at the same time; R 7 , R 8 , R 9 , R 10 and R 12 is methyl, R 5 is fluorine, and also R 4 If R is a halogen, trifluoromethyl, or cyclopropane, 6 It is not hydrogen; R 7 , R 8 , R 9 , R 10 is methyl, R 12 is methyl deuterated, and R 3 fluorine is R 5 is halogen, R 4 If R is methyl deuterated, 6 It is not methyl deuteride; R 4 , R 6 , R 7 , R 8 , R 9 , R10 is methyl, R 3 , R 5 If R is fluorine, 12 It is not methyl deuteride; R 7 , R 8 , R 9 , R 10 , R 12 is methyl, R 3 fluorine is R 5 is halogen, R 4 If there is a methylation, R 6 It is not methyl; R 7 , R 8 , R 9 , R 10 is methyl, R 12 is methyl deuterated, and R 3 fluorine is R 5 is a halogen, and also R 4 If R is methyl deuterated, 6 It is not methyl deuteride; R 4 , R 6 , R 7 , R 8 , R 9 , R 10 is methyl, R 3 and R 5 If R is fluorine, 12 It is not methyl deuterated.

[0033] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, cyano, and C. 1-3 Alkyl, C 1-3 Sulfanyl, C 2-4 Alkinyl, C 3-6 Cycloalkyls are selected from 3-6 membered heterocyclic structures containing 1-3 N, O, or S atoms, where these are halogens, C 1-3 Alkyl, C 1-3Alkyl deuterated and C 1-3 They may be further substituted with one or more substituents selected from alkoxy; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine, methyl, cyano, ethynyl, methylthio, amino, cyclopropyl, and oxetane, where they may be further substituted with halogen, methoxy, or deuterated methyl.

[0034] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 5 and R 6 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They form aryl or 5-8 membered heteroaryl compounds, where these are halogens, aminos, and C 1-3 They may be further substituted with one or more substituents selected from alkyl and oxo; Preferably, R 5 and R 6 It links with adjacent atoms to form a 5-7 membered heterocyclic structure containing 1-3 atoms selected from N, O, or S; this is a halogen, amino, C 1-3 They may be further substituted with one or more substituents selected from alkyl and oxo; More preferably, R 5 and R 6 It connects with adjacent atoms. [ka] These form halogens, amino acids, and C 1-3 It may be further substituted with one or more substituents selected from alkyl and oxo groups.

[0035] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 7 and R 8Each of these independently consists of deuterium or C 1-6 Selected from alkyl deuterated products; Preferably, R 7 and R 8 Each of these independently consists of deuterium or C 1-3 Selected from alkyl deuterated products.

[0036] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 9 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 9 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 2-6 Alkyl, C 2-6 Alkyl deuterated, C 2-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-6Alkoxy, C 2-6 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-8 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 2-6 Alkyl, C 2-6 Alkyl deuterated, C 2-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-6 Alkoxy, C 2-6 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R 9 These are selected from cyano and cyclopropyl, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 2-6 Alkyl, C 2-6 Alkyl deuterated, C 2-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-6 Alkoxy, C 2-6 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl compounds.

[0037] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 9 It is bonded to the carbon atom that is attached to it and C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Forms aryl or 5-10 member heteroaryl groups; Preferably, R 9 It is bonded to the carbon atom that is attached to it and C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-10 member heteroaryl groups; More preferably, R 9 It then bonds with the carbon atom to which it is bonded, more preferably forming a cyclopropyl molecule.

[0038] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n2 R a5 R b5 or [ka] Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include halogens, aminos, nitros, hydroxys, cyanos, oxos, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n2 R a5 R b5 or [ka] Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1 or C 1-3It may be further substituted with one or more substituents selected from alkyl groups.

[0039] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more aryl and 5-10 member heteroaryl groups; Preferably, R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more aryls and 5-8 membered heteroaryls; More preferably, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1 or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0040] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 12 C 1-3 Alkyl, C 3-6 Cycloalkyl, -(CH2) n2 R a5 R b5 or [ka] Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-3 Alkyl, C1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 12 is methyl, cyclopropyl, -(CH2) n2 R a5 R b5 or [ka] Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl compounds.

[0041] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 12 C 1-3 Selected from alkyl groups; More preferably, R 12 It is selected from methyl.

[0042] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R b5 , R a6 or R b6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryls and 5-10 membered heteroaryls; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R b5 , R a6 or R b6 Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0043] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a5 and R b5 , R a6 and R b6 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; Preferably, R a2 and R b2 , R a3 and R b3 It is linked with adjacent atoms and C 3-8 Cycloalkyls form 3-6 membered heterocyclic structures containing 1-3 heteroatoms.

[0044] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , Ra4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; More preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0045] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 Each of these atoms is linked to an adjacent atom, forming a C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 Each of these atoms is linked to an adjacent atom, forming a C 3-8 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R a2 and R b2 , R a3 and R b3 Each of these atoms is linked to an adjacent atom, forming a C 3-8 Cycloalkyls form 3-6 membered heterocyclic structures containing 1-3 heteroatoms.

[0046] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 It may be further substituted with one or more aryl and 5-10 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; More preferably, R 7 , R 8 , R 9 or R 10 Each is independently selected from methyl.

[0047] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C.1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more aryls and 5-8 membered heteroaryls; Preferably, R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, cyano, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; More preferably, R 7 , R 8 , R 9 or R 10 Each of these is independently selected from methyl, fluoro, cyclopropyl, or ethynyl.

[0048] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 7 , R 8 , R9 or R 10 Each of them is bonded to the atom it is connected to and becomes C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 Forms aryl or 5-12 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each of them is bonded to the atom it is connected to and becomes C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R 7 , R 8 , R 9 or R 10 Each of these atoms bonds with the atom it is attached to to form a cyclopropyl group.

[0049] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl compounds.

[0050] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxy, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxy, cyano, oxo, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, cyano, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Selected from; More preferably, R 7 , R 8 , R 9 or R 10 These are, independently, methyl, fluorine, cyclopropyl, ethynyl, or -(CH2)m1 Ure c1 Selected from.

[0051] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogens, aminos, nitros, hydroxys, cyanos, oxos, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R c1 The methyl group is selected from fluoro, methyl, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, or oxetane; these may be further substituted with halogens, methoxy, or deuterated methyl groups.

[0052] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 10 It connects with the atom bonded to it and adjacent atoms, forming a C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C6-12 Forms aryl or 5-12 member heteroaryl groups; Preferably, R 10 It connects with the atom bonded to it and adjacent atoms, forming a C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0053] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0054] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is as follows: R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0055] In a further preferred embodiment of the present invention, the compound represented by general formula (V) is further represented by general formula (V-1): [ka] It is represented as follows.

[0056] The object of the present invention is the general formula (XVI): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, Ring F is a 3-18 member heterocyclyl, C 3-18 Cycloalkyl, C 6-18 Selected from aryl or 5-18 member heteroaryl; Ring B is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Ring C is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Ring E is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, ring E is, [ka] Herein, this may be further substituted with one or more substituents selected from halogens, methoxy, or methyl deuterated compounds; L1, L2, or L3 are each independent, combined, C 2-4 Alkenylene, C 2-4 Alkinylene, -(CH2) n1 - or - (CH2) n5 NR b5 Selected from, where C 2-4 Alkenylene, C 2-4 Alkinylene, -(CH2) n1 - or - (CH2) n5 NR b5These are halogen, amino, nitro, hydroxyl, cyano, oxo, and C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 1 Independently, [ka] Hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 Rb2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)Ra3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 teeth, [ka] , halogen, amino, nitro, hydroxyl, cyano, oxo, -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heteroaryl, C 6-10They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; or, R 1 Each of them is bonded to the atom it is connected to and becomes C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 They form aryl or 5-14 member heteroaryl compounds, where these are [ka] Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R b5 , [ka] ,-(CH2) n1 NR a8C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; or, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a6 and Rb6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 They form aryl or 5-12 member heteroaryl compounds, where these are halogens, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where ammonia, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaromatic compounds include halogens, aminos, nitros, hydroxyls, cyanos, oxos, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 These are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryl, the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryl, the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; or, R7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 is linked to the atom to which it is attached to form a C 3-10 cycloalkyl, 3- to 10-membered heterocyclic, C 6-12 aryl or 5- to 12-membered heteroaryl; Alternatively, R 10 and R 12 are linked to the atoms to which they are attached to form a C 3-10 cycloalkyl, 3- to 10-membered heterocyclic, C 6-12 aryl or 5- to 12-membered heteroaryl; n1 to n5, m1 or x is each independently selected from 0, 1, 2, 3, 4 or 5.

[0057] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVI) is as follows: Ring F is selected from C 3-12 cycloalkyl, 3- to 14-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O or S, C 6-14 aryl or 5- to 14-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O or S; Preferably, ring F is selected from C 3-10 cycloalkyl, 5- to 14-membered heterocyclyl containing 1 to 3 heteroatoms selected from N, O or S, C 6-10 aryl or 5- to 14-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O or S; More preferably, ring F is selected from C 3-6 bridged cycloalkyl, 8- to 14-membered tricyclic fused heterocyclic containing 1 to 5 heteroatoms, 3- to 8-membered bridged heterocyclic containing 1 to 3 heteroatoms, fused heterocyclic containing 1 to 3 heteroatoms, bridged heterocyclic containing 1 to 3 heteroatoms, C 6-10 aryl or 5- to 10-membered fused heteroaryl containing 1 to 3 heteroatoms; More preferably, ring F is phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl [ka] TIFF0007898037000041.tif231165 Selected from TIFF0007898037000042.tif48165.

[0058] Note: [ka] This indicates that it is bound to L1.

[0059] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring F consists of phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl, [ka] TIFF0007898037000045.tif241166 Selected from TIFF0007898037000046.tif68165.

[0060] Note: [ka] This indicates that it is bound to L1.

[0061] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring B is C 3-8Cycloalkyl, 3-8 membered heterocyclyl containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy or C 1-3 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Preferably, ring B is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogen, amino, oxo, thio, or C 1-3 The alkyl group may be further substituted with one or more substituents; More preferably, ring B is [ka] Selected from, where these are halogen, amino, oxo, thio or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0062] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring C is C 3-8 A 3-8 membered heterocyclic structure containing 1-3 elements selected from cycloalkyl, N, O, or S, C 6-10Selected from 5-8 membered heteroaryls containing aryl or 1-3 selected from N, O, or S, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy or C 1-3 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Preferably, ring C is C 3-6 A 3-6 member heterocyclic structure containing 1-3 elements selected from cycloalkyl, N, O, or S, C 6-10 Selected from 5-6 membered heteroaryls containing aryl or 1-3 selected from N, O, or S, where these are hydroxyl, thio, oxo, or C 1-6 They may be further substituted with one or more substituents selected from haloalkoxys; More preferably, ring C is [ka] These are selected from, where they may be further substituted with one or more substituents selected from hydroxyl, thio, or oxo.

[0063] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring E is C 3-12 Cycloalkyl, 3-12 member heterocyclic structure containing 1-3 N, O, or S atoms, C 6-12Selected from aryl or 5-12 membered heteroaryls containing 1-3 N, O, or S atoms, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, ring E is C 3-6 Cycloalkyl, 3-10 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryls or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms, these may be further substituted with one or more substituents selected from halogens, methoxy, or deuterated methyl atoms; More preferably, ring E is [ka] These are selected from, where they may be further substituted with one or more substituents selected from halogens, methoxy, or methyl deuterated compounds.

[0064] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring E is, [ka] Herein, this may be further substituted with one or more substituents selected from halogens, methoxy, or methyl deuterated compounds.

[0065] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 1 Independently, [ka] Hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 teeth, [ka] , halogen, amino, nitro, hydroxyl, cyano, oxo, -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heteroaryl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 Independently, [ka] Hydrogen, deuterium, amino, oxo, fluorine, chlorine, bromine, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cross-linked cycloalkyl, C 3-8 Spirocycloalkyl, 3-8 membered spiroheterocyclic with 1-3 heteroatoms, 5-8 membered heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 Rb2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cross-linked cycloalkyl, C 3-8 Spirocycloalkyl, 3-8 membered spiroheterocyclic with 1-3 heteroatoms, 5-8 membered heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 Rb6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 teeth, [ka] , halogen, cyano or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0066] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: More preferably, R 1 Independently, [ka] Hydrogen, deuterium, amino, oxo, cyano, fluorine, chlorine, bromine, methyl, ethyl, cyclopropyl, -CD3, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 Rb6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where, the amino, methyl, ethyl, cyclopropyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 Rb10 teeth, [ka] , halogen, cyano or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0067] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 1 Each of them is bonded to the atom it is connected to and becomes C 3-6 A 3-10 membered heterocyclic structure containing 1-3 elements selected from cycloalkyl, N, O, or S, C 6-10 It forms a 5-8 membered heteroaryl compound containing 1 to 3 members selected from aryl or N, O, or S, where these are [ka] Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 Rb4 ,-(CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R b5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; Preferably, R 1 Each of them is bonded to the atom it is connected to and becomes C 3-4 It forms a 5-7 membered heterocyclic structure containing 1 to 3 elements selected from cycloalkyl, N, O, or S, where these are [ka] , deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 Cycloalkyl, amino, oxo, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R b5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; More preferably, R 1 Each of these bonds with the atom it is attached to to form a cyclopropyl group, where this is [ka] , deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 Cycloalkyl, amino, oxo, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R b5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2)n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 It may be further substituted with one or more substituents selected from the following:

[0068] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from N, O, or S, C 6-10 Selected from aryl or 5-6 membered heteroaryls containing 1 to 3 heteroatoms selected from N, O, or S, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from N, O, or S, C 6-10 A 5-6 membered heteroaryl containing aryl or 1-3 heteroatoms selected from N, O, or S is a halogen or C 1-3 The alkyl group may be further substituted with one or more substituents; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10 These are, independently, hydrogen, deuterium, halogen, methyl, ethyl, cyano, deuterated methyl, cyclopropyl, cyclopentyl, phenyl, [ka] Selected from, where methyl, ethyl, deuterated methyl, cyclopropyl, cyclopentyl, phenyl, phenyl [ka] It may be further substituted with one or more fluorine atoms.

[0069] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a6 and R b6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-8 A 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from cycloalkyl, N, O, or S, C 6-10 Forms 5-8 membered heteroaryls containing aryl or 1-3 heteroatoms selected from N, O, or S, where these are halogen, amino, nitro, cyano, oxo, or C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and Rb4 , R a6 and R b6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-6 It forms a 3-6 membered heterocyclic structure containing 1-3 heteroatoms selected from cycloalkyl, N, O, or S, where these are halogen, amino, thio, or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0070] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine, cyano, cyclopropyl, or methyl, where the cyclopropyl or methyl may be further substituted with one or more substituents selected from deuterium, methyl deuteride, methyl, cyclopropyl, or oxo.

[0071] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C.1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, or -(CH2) m1 Ure c1 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, or -(CH2) m1 Ure c1 These are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, cyano, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Selected from, where C 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 This may be further substituted with one or more substituents selected from deuterium, methyl deuterated, methyl, cyclopropyl, or oxo; More preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 Each of these is independently cyano, methyl, fluoro, cyclopropyl, ethynyl, or -(CH2) m1 Ure c1 These are selected from, where they may be further substituted with one or more substituents selected from deuterium, methyl deuterated, methyl, cyclopropyl, or oxo.

[0072] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 Each of these is independently cyano, methyl, fluoro, cyclopropyl, ethynyl, or -(CH2) m1 Ure c1 These are selected from, where they may be further substituted with one or more substituents selected from deuterium, methyl deuterated, methyl, cyclopropyl, or oxo.

[0073] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R c1 This is selected from fluorine, methyl, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, or oxetane, where the methyl, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, or oxetane may be further substituted with one or more substituents of halogen, methoxy, or deuterated methyl.

[0074] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 It connects with the atom bonded to it and C 3-6 Cycloalkyl, 3-8 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Forms an aryl or 5-8 membered heteroaryl containing 1-3 N, O, or S atoms; Preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 It connects with the atom bonded to it and C 3-6 Cycloalkyl, 3-6 member heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Forms an aryl or 5-8 membered heteroaryl containing 1-3 N, O, or S atoms; More preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 or R 15 It is linked to the atom it is bonded to and becomes cyclopropyl or [ka] It forms.

[0075] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 10 and R 12 It connects with the atoms bonded to them and C 3-8 Cycloalkyl, 3-8 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Forms an aryl or 5-10 membered heteroaryl containing 1-3 N, O, or S atoms; Preferably, R 10 and R 12 It connects with the atoms bonded to them and C 3-6 Cycloalkyl, 3-6 member heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Forms an aryl or 5-8 membered heteroaryl containing 1-3 N, O, or S atoms; More preferably, R 10 and R 12 It connects with the atoms bonded to them. [ka] It forms.

[0076] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0077] In further preferred embodiments of the present invention, the compound represented by general formula (XVI) is as follows: Ring F consists of phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl, [ka] TIFF0007898037000076.tif231166 Selected from TIFF0007898037000077.tif26155.

[0078] Note: [ka] This indicates that it is bound to L1.

[0079] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVI) is further represented by the general formula (XVI-1): [ka] It is represented as follows.

[0080] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVI) is further represented by the general formula (XVI-A): [ka] It is represented as, Here, in the above formula, R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 They form aryl or 5-14 member heteroaryl compounds, where these are [ka] Hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; or, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)Ra1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 These are halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; or, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a6 and R b6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12They form aryl or 5-12 member heteroaryl groups, where these are halogen, amino, nitro, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Ring B, Ring C, Ring E, L1, L2, L3, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 14 , R 15 n1, n2, n3, n4, n5, m1 and x are as defined in general formula (XVI).

[0081] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-6 A 3-10 membered heterocyclic structure containing 1-3 elements selected from cycloalkyl, N, O, or S, C 6-10It forms a 5-8 membered heteroaryl compound containing 1 to 3 members selected from aryl or N, O, or S, where these are [ka] Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2)n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; Preferably, R 1 and R 2 , R 1 and R 11 Each of these atoms is linked to an adjacent atom to form a 5-7 member heterocyclic structure containing 1 to 3 atoms selected from N, O, or S, where these are, [ka] , deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 Cycloalkyl, amino, oxo, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 They may be further substituted with one or more substituents selected from; More preferably, R 1 and R 2 , R1 and R 11 It is linked to the adjacent phenyl [ka] TIFF0007898037000090.tif225165 TIFF0007898037000091.tif27163 is formed, where these are NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 , [ka] , deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo.

[0082] Note: [ka] This indicates that it is bound to L1.

[0083] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 These are halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, amino, oxo, fluorine, chlorine, bromine, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cross-linked cycloalkyl, C 3-8 Spirocycloalkyl, 3-8 membered spiroheterocyclic with 1-3 heteroatoms, 5-8 membered heteroaryl, -NS(O)R a1 R b1 ,-(CH2)n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cross-linked cycloalkyl, C 3-8 Spirocycloalkyl, 3-8 membered spiroheterocyclic with 1-3 heteroatoms, 5-8 membered heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2)n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 is halogen, cyano or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0084] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from N, O, or S, C 6-10 Selected from a 5-6 membered heterocyclic formula containing aryl or 1-3 heteroatoms selected from N, O, or S, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from N, O, or S, C 6-10 A 5-6 membered heteroaryl containing aryl or 1-3 heteroatoms selected from N, O, or S is a halogen or C. 1-3 The alkyl group may be further substituted with one or more substituents; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 or R b10These are, independently, hydrogen, deuterium, halogen, methyl, ethyl, cyano, deuterated methyl, cyclopropyl, cyclopentyl, and phenyl [ka] Selected from, where methyl, ethyl, deuterated methyl, cyclopropyl, cyclopentyl, phenyl, phenyl [ka] It may be further substituted with one or more fluorine atoms.

[0085] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVA) is as follows: R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a6 and R b6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-8 A 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from cycloalkyl, N, O, or S, C 6-10 Forms 5-8 membered heteroaryls containing aryl or 1-3 heteroatoms selected from N, O, or S, where these are halogen, amino, nitro, cyano, oxo, or C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 , R a6 and R b6 , R a8 and R b8 , R a9 and R b9 , R a10 and R b10 It is linked with adjacent atoms and C 3-6 It forms a 3-6 membered heterocyclic structure containing 1 to 3 heteroatoms selected from cycloalkyl, N, O, or S.

[0086] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: In general formula (XVI-A), [ka] Furthermore, the following is shown: [ka] Here, these are halogens, methoxy, and C 1-3 Cycloalkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl; Ring M1, Ring M2, Ring M3, Ring M4, Ring M5, Ring M6, Ring M7, Ring M8, M9 or M 10 Each of them is independent of C 3-12Cycloalkyl, 3-12 membered heterocyclyl, C 6-12 Selected from aryl or 5-12 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0087] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: In general formula (XVI-A), [ka] Furthermore, the following is shown: [ka] TIFF0007898037000105.tif26132 Here, these are halogen, methoxy, C 1-3 Cycloalkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl; Ring M1, Ring M2, Ring M3, Ring M4, Ring M5, Ring M6, Ring M7, Ring M8, M9 or M 10Each of them is independent of C 3-8 Cycloalkyl, 3-8 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, ring M1, ring M2, ring M3, ring M4, ring M5, ring M6, ring M7, ring M8, M9 or M 10 Each of them is independent of C 3-6 Cycloalkyl, 3-6 member heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogens, methoxy, and C 1-3 Cycloalkyl, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl compounds.

[0088] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: In general formula (XVI-A), [ka] Furthermore, the following is shown: [ka] Here, these are halogens, methoxy, and C 1-3 Cycloalkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl; Rings M1, M2, M3, M4, M5, M6, M7, or M8 are each independently of C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-12 Selected from aryl or 5-12 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0089] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: In general formula (XVI-A), [ka] Furthermore, the following is shown: [ka] Here, these are halogens, methoxy, and C 1-3 Cycloalkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl; Rings M1, M2, M3, M4, M5, M6, M7, or M8 are each independently of C 3-8 Cycloalkyl, 3-8 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, ring M1, ring M2, ring M3, ring M4, ring M5, ring M6, ring M7, or ring M8 are each independently C 3-6 Cycloalkyl, 3-6 member heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogens, methoxy, and C 1-3Cycloalkyl, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl or deuterated methyl compounds.

[0090] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is as follows: R 1 and R 2 , R 1 and R 11 It is linked to the adjacent phenyl [ka] TIFF0007898037000111.tif242166 This forms TIFF0007898037000112.tif144168, where these are -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 ,-(CH2) n1 S(O)2R b5 or -(CH2) n5 C(O)NR a10 R b10 , [ka] , deuterium, halogen, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo.

[0091] Note: [ka] L 1 This indicates that it is bound to something.

[0092] In a further preferred embodiment of the present invention, the compound represented by general formula (XVI-A) is further represented by general formula (XVI-B): [ka] It is represented as follows.

[0093] The object of the present invention is the general formula (II): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 Forms an aryl or 5-14 member heteroaryl, where the C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 Aryl or 5-14 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 1 , R 2 , R 3 or R 11 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogens, aminos, nitros, hydroxys, cyanos, oxos, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 7 , R 8 , R 9 or R 10 It connects with the atom bonded to it and C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 Forms aryl or 5-12 member heteroaryl groups; n1 is an integer between 0 and 5; m1 is an integer between 0 and 5.

[0094] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0095] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-10 membered heterocyclic, C 6-10 They form aryl or 5-8 member heteroaryl compounds, where these are halogens, C 1-3 They may be further substituted with one or more substituents selected from alkyl, amino, or oxo; Preferably, R 1 and R 2 , R 1 and R11 These atoms are linked to adjacent atoms to form a 5-7 member heterocyclic structure containing 1 to 3 atoms selected from N, O, or S, and these may be further substituted with oxos.

[0096] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 and R 2 , R 1 and R 11 It connects with adjacent atoms. [ka] These form halogens, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo.

[0097] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They form aryl or 5-8 membered heteroaryl compounds, which may be further substituted with one or more substituents selected from halogens, aminos, or oxos; Preferably, R 1 and R 2 , R 1 and R 11 These atoms are linked to adjacent atoms to form a 5-7 member heterocyclic structure containing 1 to 3 atoms selected from N, O, or S, and these may be further substituted with oxos.

[0098] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 3These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Furthermore, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Alkyl halides, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Alkyl halides are -NS(O)R a1 R b1 or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0099] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)Ra1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1 or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0100] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0101] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It forms an aryl or 5-8 membered heteroaryl.

[0102] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 It forms a cycloalkyl or a 3-6 membered heterocyclic structure containing 1-3 heteroatoms.

[0103] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine or methyl.

[0104] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 or R 10Each is independently selected from methyl.

[0105] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 1 and R 2 , R 1 and R 11 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-10 membered heterocyclic, C 6-10 They form aryl or 5-8 member heteroaryl compounds, where these are halogens, C 1-3 Alkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo; Preferably, R 1 and R 2 , R 1 and R 11 It links with adjacent atoms to form a 5-7 member heterocyclic structure containing 1 to 3 atoms selected from N, O, or S, where these are C 3-6 They may be further substituted with cycloalkyl or oxo groups; More preferably, R 1 and R 2 , R 1 and R 11 It connects with adjacent atoms. [ka] TIFF0007898037000120.tif115160 is formed, where these are halogens, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo.

[0106] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 4 , R 5 or R6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, and C. 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluoro, cyano, cyclopropyl, or methyl.

[0107] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each of these is independently selected from methyl or cyclopropyl.

[0108] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0109] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 7 , R 8 , R 9 or R 10 Each of them is bonded to the atom it is connected to and becomes C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-12 Forms aryl or 5-12 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each of them is bonded to the atom it is connected to and becomes C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R 7 , R 8 , R 9 or R 10 Each of these atoms bonds with the atom it is attached to to form a cyclopropyl group.

[0110] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 10 It connects with the atom bonded to it and adjacent atoms, forming a C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 Forms aryl or 5-12 member heteroaryl groups; Preferably, R 10 It connects with the atom bonded to it and adjacent atoms, forming a C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0111] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 10 It connects with the atom bonded to it and with adjacent atoms. [ka] It forms.

[0112] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R c1 This is selected from fluorine, methyl, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl, or oxetane, where these may be further substituted with halogen, methoxy, or deuterated methyl.

[0113] In further preferred embodiments of the present invention, the compound represented by general formula (II) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-6Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, or -(CH2) m1 Ure c1 Selected from, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R 7 , R 8 , R9 or R 10 These are, independently, hydrogen, deuterium, halogen, cyano, and C. 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Selected from; More preferably, R 7 , R 8 , R 9 or R 10 These are, independently, methyl, fluorine, cyclopropyl, ethynyl, or -(CH2) m1 Ure c1 Selected from.

[0114] In a further preferred embodiment of the present invention, the compound represented by general formula (II) is further represented by general formula (II-1): [ka] It is represented as follows.

[0115] The object of the present invention is the general formula (XI): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, Ring E is C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 Selected from aryl or 5-14 member heteroaryl; L2 is a bond, -(CH2) n4 -, C 2-4 Alkenil, C 2-4 Selected from Alkinir; R 1 , R 2 , R 3 or R 11These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n P(O)R a7 R b7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 7 , R 8 , R 9 or R 10 It connects with the atom bonded to it and C 3-10Cycloalkyl, 3-10 membered heterocyclic, C 6-12 Forms aryl or 5-12 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 or R b9 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 members; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 and R b9 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , Ra5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 or R b9 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 members; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 and R b9 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 through n4 are integers between 0 and 5.

[0116] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Ring E is C 3-8 Cycloalkyl, 3-10 membered heterocyclic structure containing 1-3 N, O, or S atoms, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms; Preferably, ring E is [ka] Selected from.

[0117] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Ring E is, [ka] Selected from.

[0118] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Ring E is, [ka] Selected from.

[0119] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 , R 2 , R 3 or R 11These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0120] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Preferably, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n P(O)R a7 Rb7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0121] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0122] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 and R 2 or R 1 and R 11 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] It may be further substituted with one or more substituents selected from the following:

[0123] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Preferably, R 1 and R 2 or R 1 and R 11 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They form aryl or 5-8 member heteroaryl groups, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] They may be further substituted with one or more substituents selected from; More preferably, R 1 and R 2 or R 1 and R 11It links with adjacent atoms to form a 5-7 membered heterocyclic structure containing 1 to 3 atoms selected from phenyl, N, O, or S, where these are oxo, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] It may be further substituted with one or more substituents selected from the following:

[0124] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 and R 2 or R 1 and R 11 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 They form aryl or 5-10 member heteroaryl groups, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NRa2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n P(O)R a7 R b7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 They may be further substituted with one or more substituents selected from; Preferably, R 1 and R 2 or R 1 and R 11 It links with adjacent atoms to form a 5-7 membered heterocyclic structure containing 1 to 3 atoms selected from phenyl, N, O, or S, where these are methyl, halogen, oxo, and NS(O)R. a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n P(O)R a7 R b7 or -(CR a8 Rb8 ) n4 C(O)NR a9 R b9 They may be further substituted with one or more substituents selected from; More preferably, R 1 and R 2 or R 1 and R 11 It connects with adjacent atoms. [ka] They form, where these are methyl, halogen, oxo, and NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] ,-(CH2) n P(O)R a7 R b7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 It may be further substituted with one or more substituents selected from the following:

[0125] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 and R 2 or R 1 and R 11 It connects with adjacent atoms. [ka] It forms.

[0126] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 Cycloalkyl, C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine, methyl, and cyclopropyl.

[0127] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each of these is independently selected from hydrogen or methyl.

[0128] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 or R b6These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryls, 5-10 member heteroaryls; or, R a1 and R b1 or R a2 and R b2 or R a3 and R b3 or R a4 and R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl compounds.

[0129] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R a1 , R b1 , R a2 , Rb2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 or R b9 These are, independently, hydrogen, deuterium, halogen, amino, cyano, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 member heteroaryl; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 or R b9 Each is independently hydrogen, deuterium, halogen, cyano, cyclopropyl, cyclopentyl, methyl, ethyl, phenyl or [ka] Selected from.

[0130] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , Ra5 , R a6 or R b6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Selected from haloalkyl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 or R b6 Each of these is independently selected from hydrogen, deuterium, halogen, and methyl.

[0131] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: Ring E is, [ka] That is the case.

[0132] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, cyano, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 Cycloalkyl or C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluoro, methyl, cyano, or cyclopropyl.

[0133] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R7 , R 8 , R 9 or R 10 It connects with the atom bonded to it and C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 Forms aryl or 5-12 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 or R 10 It connects with the atom bonded to it and C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Forms aryl or 5-8 member heteroaryl groups; More preferably, R 7 , R 8 , R 9 or R 10 It then bonds with the atom it is attached to to form a cyclopropyl group.

[0134] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 or R b9 Each is independently hydrogen, deuterium, halogen, cyano, cyclopropyl, cyclopentyl, methyl, ethyl, deuterated methyl, phenyl or [ka] Selected from.

[0135] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R a1 and R b1 or R a2 and R b2 or R a3 and R b3 or R a4 and R b4 or R a7 and R b7 or R a8 and R b8 or R a9 and R b9 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Forms an aryl or 5-8 member heteroaryl, where the C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R a1 and R b1 or R a2 and R b2 or R a3 and R b3 or R a4 and R b4 or R a7 and R b7 or R a8 and R b8 or R a9 and R b9 It links with adjacent atoms to form a cyclopropyl group.

[0136] In further preferred embodiments of the present invention, the compound represented by general formula (XI) is as follows: R 1 and R 2 or R 1 and R 11 It links with adjacent atoms to form a 5-7 membered heterocyclic structure containing 1 to 3 atoms selected from phenyl, N, O, or S, where these are methyl, halogen, oxo, cyclopropyl, and NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] , (CH2) n1 P(O)R a7 R b7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 They may be further substituted with one or more substituents selected from; Preferably, R 1 and R 2 or R 1 and R 11 It connects with adjacent atoms. [ka] These form methyl, halogen, oxo, cyclopropyl, and NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)Ra3 R b3 , -NR a5 S(O)NR a4 R b4 , (CH2) n1 S(O)2R a5 ,-(CH2) n1 O(CH2) n2 R a5 , [ka] , (CH2) n1 P(O)R a7 R b7 or -(CR a8 R b8 ) n4 C(O)NR a9 R b9 It may be further substituted with one or more substituents selected from the following:

[0137] In a further preferred embodiment of the present invention, the compound represented by general formula (XI) is further represented by general formula (XI-1): [ka] It is represented as follows.

[0138] The object of the present invention is the general formula (XV): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 1 , R 2 , R 3 , R 11 It is linked with adjacent atoms and C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 Forms an aryl or 5-14 member heteroaryl, where the C 3-12 Cycloalkyl, 3-12 membered heterocyclic, C 6-14 Aryl or 5-14 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9, R b9 , R a10 , R b10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 member, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member groups include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R. a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R a1 and R b1 or R a2 and R b2 or R a3 and R b3 or Ra4 and R b4 or R a6 and R b6 or R a8 and R b8 or R a9 and R b9 or R a10 and R b10 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Ring A is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, mercapto, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy or C 1-6 They may be further substituted with one or more substituents selected from haloalkoxys; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C.1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 It connects with the atom bonded to it and C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-12 Forms aryl or 5-12 member heteroaryl groups; n1 to n5 are integers from 0 to 5; x is an integer between 0 and 5.

[0139] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, 5-8 membered heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CR a8 Rb8 ) n4 C(O)NR a9 R b9 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or C 2-4 Alkynnyl is a halogen, -NS(O)R a1 R b1 , C 1-3 Alkyl or C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl groups; More preferably, R 1 , R 2 , R 3 or R 11 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 2-4 Alkinyl, C 3-8 Cross-linked cycloalkyl, C 3-8 Spirocycloalkyl, 3-8 membered spiroheterocyclic with 1-3 heteroatoms, 5-8 membered heteroaryl, NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CR a8 R b8 ) n4 C(O)NR a9 R b9 or -(CH2) n5 C(O)NR a10 R b10 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or C 2-4 Alkynnyl is a halogen, -NS(O)R a1 R b1 , C 1-3 Alkyl or C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl groups.

[0140] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R 1 and R 2 or R 1 and R 11 It is linked with adjacent atoms and C 3-6 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They form aryl or 5-8 member heteroaryl compounds, where these are halogens, C 1-3 Alkyl, C 3-6 They may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo; Preferably, R 1 and R 2 or R 1 and R 11 It is linked with adjacent atoms to form a 5-7 member heterocyclic structure containing 1 to 3 atoms selected from N, O, or S, where these are C 3-6 They may be further substituted with cycloalkyl or oxo groups; More preferably, R 1 and R 2 or R 1 and R 11 It is linked to the adjacent phenyl, [ka] TIFF0007898037000153.tif27146 is formed, where these are halogens, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 3-6 It may be further substituted with one or more substituents selected from cycloalkyl, amino, or oxo.

[0141] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 , R b10 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, 3-8 membered heterocyclic structure containing 1-3 heteroatoms selected from N, O, or S, C 6-10 Selected from aryl or 5-6 membered heteroaryls containing 1 to 3 heteroatoms selected from N, O, or S, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 3-6 Cross-linked cycloalkyl, C 3-6 Spirocycloalkyl, a 3-8 membered heterocyclic group containing 1-3 heteroatoms selected from N, O, or S, C 6-10A 5-6 membered heteroaryl containing aryl or 1-3 heteroatoms selected from N, O, or S is a halogen or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 , R b8 , R a9 , R b9 , R a10 , R b10 These are, independently, hydrogen, deuterium, halogen, methyl, methyl deuterated, cyclopropyl, [ka] Selected from, where these may be further substituted with fluorine.

[0142] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R a1 and R b1 or R a2 and R b2 or R a3 and R b3 or R a4 and R b4 or R a6 and R b6 or R a8 and R b8 or R a9 and R b9 or R a10 and R b10 It connects with adjacent atoms to form C 3-8 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 Forms aryl or 5-8 membered heteroaryl groups; Preferably, Ra1 and R b1 or R a2 and R b2 or R a3 and R b3 or R a4 and R b4 or R a6 and R b6 or R a8 and R b8 or R a9 and R b9 or R a10 and R b10 It is linked with adjacent atoms and C 3-6 It forms a cycloalkyl or a 3-6 membered heterocyclic structure containing 1-3 heteroatoms.

[0143] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: Ring A is C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, oxo, mercapto, thio, or C 1-6 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring A is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclines containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms; these are halogen, amino, oxo, mercapto, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; More preferably, ring A is [ka] Selected from.

[0144] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R 4 , R 5 or R 6These are, independently, hydrogen, deuterium, halogen, amino, cyano, and C. 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluoro, cyano, cyclopropyl, or methyl.

[0145] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 These are, independently, hydrogen, deuterium, halogen, and C. 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 Each of these is independently selected from methyl or cyclopropyl.

[0146] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is as follows: R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 It connects with the atom bonded to it and C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; Preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 or R 14 It then bonds with the atom it is attached to to form a cyclopropyl group.

[0147] In a further preferred embodiment of the present invention, the compound represented by general formula (XV) is further represented by general formula (XV-1): [ka] It is represented as follows.

[0148] The object of the present invention is the general formula (IV): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, L1 and L2 are independent of each other, and are joined, C 2-4 Alkenyl group, C 2-4 Alkinyl, -(CH2) n2 -,-(CH2) n3 NR b5 Selected from; Ring B is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; R b5 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryls and 5-10 membered heteroaryls; R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 is an integer between 0 and 5; n² is an integer between 0 and 5; n3 is an integer between 0 and 5.

[0149] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: L1 and L2 are independent of each other, bonded, -(CH2) n3 NR b5 Selected from.

[0150] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: Ring B is C 3-6Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms; these are deuterium, halogens, amino, oxo, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring B is [ka] Selected from.

[0151] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: Ring B is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms; these are deuterium, halogens, amino, oxo, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring B is [ka] Selected from.

[0152] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: Ring B is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-10 membered heteroaryls containing 1-3 N, O, or S atoms; these are deuterium, halogens, amino, oxo, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring B is [ka] Selected from.

[0153] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more aryls and 5-8 membered heteroaryls; Preferably, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1 or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0154] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0155] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R a1 and R b1 , R a2 and R b2 , R a3 and R b3 , R a4 and R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It forms an aryl or 5-8 membered heteroaryl.

[0156] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R a2 and R b2 , R a3 and R b3 It is linked with adjacent atoms and C 3-8 It forms a cycloalkyl group or a 3-6 membered heterocyclic structure containing 1-3 heteroatoms.

[0157] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine or methyl.

[0158] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R 7 , R8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each is independently selected from methyl.

[0159] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R 12 C 1-3 Selected from alkyl groups; Preferably, R 12 It is selected from methyl.

[0160] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: Ring B is, [ka] Selected from.

[0161] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is as follows: R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 12 C 1-3 Alkyl or C 3-6 Selected from cycloalkyl groups; More preferably, R 12 It is selected from methyl or cyclopropyl.

[0162] In a further preferred embodiment of the present invention, the compound represented by general formula (IV) is further represented by general formula (IV-1): [ka] It is represented as follows.

[0163] The object of the present invention is the general formula (VI): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, Ring C is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, -NR a6 S(O)2R b6 They may be further substituted with one or more substituents selected from; R 10 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aromatic or 5-10 member heteroaryl compounds; Alternatively, R 10 It is linked to the bonded C atom and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a6 and R b6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryls and 5-10 membered heteroaryls; Here, R 3 fluorine is R 4 and R 6 is methyl, R 5 fluorine is R 7 and R 8 is hydrogen or methyl, R 12 is methyl, and ring C is [ka] If R 10 It cannot be methyl at the same time; R 3 fluorine is R 4 and R 6 is methyl, R 5 fluorine is R 7 and R8 is hydrogen, R 12 is methyl, and ring C is [ka] If R 10 It cannot be hydroxymethyl at the same time; R 3 fluorine is R 4 and R 6 is methyl, R 5 fluorine is R 7 and R 8 is hydrogen, R 12 is methyl, and ring C is [ka] If R 10 At the same time [ka] It is not possible to be; R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 It may be further substituted with one or more aryl and 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Alternatively, R a1 , R b1 , Ra2 , R b2 , R a3 , R b3 , R a4 and R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 is an integer between 0 and 5.

[0164] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: Ring C is C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, -NR a6 S(O)2R b6 They may be further substituted with one or more substituents selected from; Preferably, ring C is C 3-8 Selected from cycloalkyl, 3-8 membered heterocyclic compounds containing 1-3 atoms selected from N, O, or S, and 5-8 membered heteroaryl compounds containing 1-3 atoms selected from N, O, or S, where these are hydroxyl, oxo, and -NR. a6 S(O)2R b6 They may be further substituted with one or more substituents selected from; More preferably, ring C is [ka] Selected from, where these are hydroxyl, oxo, and -NR a6 S(O)2R b6 It may be further substituted with one or more substituents selected from the following:

[0165] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R 10 is hydrogen, deuterium, halogen, C 1-3 Selected from alkyl groups; Preferably, R 10 It is selected from methyl.

[0166] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R 10 It is linked to the bonded C atom and C 3-6 Forms a cycloalkyl group; Preferably, R 10 It is linked to the bonded C atom and C 3-6 It forms a cycloalkyl group.

[0167] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R a6 and R b6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-3 Alkenil, C 2-3 Alkinyl, C 3-8 Cycloalkyl, 5-7 membered heterocyclic, C 6-10 Selected from aryls and 5-8 member heteroaryls; Preferably, R a6 and R b6 Each of these is independently selected from hydrogen or methyl.

[0168] R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more aryls and 5-8 membered heteroaryls; Preferably, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1 or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0169] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0170] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R a1と R b1 , R a2と R b2 , R a3と R b3 , R a4と R b4 Each of these atoms is linked to an adjacent atom, forming a C 3-8 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 It forms a cycloalkyl or a 3-6 membered heterocyclic structure containing 1-3 heteroatoms.

[0171] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluorine or methyl.

[0172] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 7 , R 8 , R 9 or R 10 Each is independently selected from methyl.

[0173] In further preferred embodiments of the present invention, the compound represented by general formula (VI) is as follows: R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 12 C 1-3 Selected from alkyl groups; More preferably, R 12 It is selected from methyl.

[0174] In a further preferred embodiment of the present invention, the compound represented by general formula (VI) is further represented by general formula (VI-1): [ka] It is represented as follows.

[0175] The object of the present invention is the general formula (VII): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, Ring D is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl; R 13 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 is an integer between 0 and 5; x is an integer between 0 and 5.

[0176] Here, R 3 is hydrogen, R 4 and R 6 is methyl, R 5 is fluorine, and also R 9 , R 10 and R 12 If R is methyl, 10 At the same time [ka] It cannot be that way.

[0177] In further preferred embodiments of the present invention, the compound represented by general formula (VII) is as follows: Ring D is selected from a 5-12 membered bicyclic condensed heterocyclic ring, a 5-12 membered bicyclic spiroheterocyclic ring, and a 5-12 membered bicyclic bridged heterocyclic ring; Ring D is preferably a 5-8 membered bicyclic condensed heterocyclic ring, a 5-8 membered bicyclic spiroheterocyclic ring, or a 5-8 membered bicyclic bridging heterocyclic ring; Ring D is more preferably, [ka] That is the case.

[0178] In further preferred embodiments of the present invention, the compound represented by general formula (VII) is as follows: R 13 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Selected from aryl or 5-8 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; R 13 It is selected from methyl.

[0179] In further preferred embodiments of the present invention, the compound represented by general formula (VII) is as follows: Ring D is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl; R 13 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Selected from aryl or 5-8 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms an aryl or 5-10 member heteroaryl, where the C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 It is linked with adjacent atoms and C 3-8 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Forms aryl or 5-8 member heteroaryl groups; R 4 , R 5 or R 6These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryls, where these are halogen, amino, nitro, hydroxy, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; n1 is an integer between 0 and 5; x is an integer between 0 and 5.

[0180] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: Ring D is selected from 3-8 member monocyclic heterocyclic, 5-12 member bicyclic condensed heterocyclic, 5-12 member bispyroheterocyclic, and 5-12 member bicyclic bridged heterocyclic; Preferably, ring D is selected from a 5-6 member monocyclic heterocyclic, a 5-10 member bicyclic condensed heterocyclic, a 5-10 member bispyroheterocyclic, or a 5-8 member bicyclic bridged heterocyclic; More preferably, ring D is [ka] Selected from.

[0181] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 13 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10Selected from aryl or 5-8 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 13 It is selected from methyl.

[0182] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 3 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NRa4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 It may be further substituted with one or more aryls and 5-8 membered heteroaryls; Preferably, R 3 These are hydrogen, deuterium, halogens, amino acids, and C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 or -NR a5 S(O)NR a4 R b4 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Haloalkyls are halogens, -NS(O)R a1 R b1or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0183] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 or R b4 Each of these elements is independently selected from hydrogen, deuterium, halogen, or methyl.

[0184] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R a2 and R b2 , R a3 and R b3 Each atom is independent and connects with the adjacent atom to form a carbon atom. 3-8 It forms a cycloalkyl or a 3-6 membered heterocyclic structure containing 1-3 heteroatoms.

[0185] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluoro or methyl.

[0186] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R 9 or R 10 Each is independently selected from methyl.

[0187] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 12 C 1-3 Selected from alkyl groups; Preferably, R 12 It is selected from methyl.

[0188] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: Ring D is, [ka] Selected from.

[0189] In another embodiment of the present invention, the compound represented by general formula (VII) is as follows: R 12 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 12 C 1-3 Alkyl or C 3-6 Selected from cycloalkyl groups; More preferably, R 12 It is selected from methyl or cyclopropyl.

[0190] In a further preferred embodiment of the present invention, the compound represented by formula (VII) is further represented by formula (VII-1): [ka] It is represented as follows.

[0191] The object of the present invention is the general formula (XII): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, L1 is a bond, C alkenylene, C alkynylene, -(CH2) n4 -,-(CH2) n5 NRb5 Selected from, where C is alkenylene, C is alkynylene, -(CH2) n4 - or - (CH2) n5 NR b5 These include halogens, aminos, nitros, hydroxyls, cyanos, oxos, C alkyls, C deuterated alkyls, C haloalkyls, C hydroxyalkyls, C alkoxys, C haloalkoxys, C alkenyls, C alkynyls, and C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Ring F is C 3-12 Cycloalkyl, 3-14 member heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl; R 1 These are independently hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2R a5 、 -(CH2) n1 C(O)NR a6 R b6 、 -(CH2) n1 P(O)R a3 R b3 、

Chem.

[0192] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Ring F is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl.

[0193] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Preferably, ring F is C 3-10 Cycloalkyl, 5-14 member heterocyclyl, C 6-10 Selected from aryl or 5-10 membered heteroaryl; More preferably, ring F is C 3-6 Cross-linked cycloalkyl, 8-14 member tricyclic condensed heterocyclic with 1-5 heteroatoms, 3-8 member cross-linked heterocyclic with 1-3 heteroatoms, condensed heterocyclic with 1-3 heteroatoms, cross-linked heterocyclic with 1-3 heteroatoms, C 6-10 Selected from aryl or 5-10 membered condensed heteroaryls containing 1-3 heteroatoms; More preferably, ring F is phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl [ka] Selected from TIFF0007898037000179.tif28140.

[0194] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Ring F consists of phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl, [ka] Selected from.

[0195] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Ring F is C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-10 Selected from aryl or 5-10 membered heteroaryl; Preferably, ring F is C 3-6 Cross-linked cycloalkyl, 3-8 membered cross-linked heterocyclic, containing 1-3 heteroatoms, condensed heterocyclic, containing 1-3 heteroatoms, cross-linked heterocyclic, C 6-10 Selected from aryl or 5-10 membered condensed heteroaryls containing 1-3 heteroatoms; More preferably, ring F is phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl [ka] Selected from.

[0196] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Ring F consists of phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl, [ka] Selected from.

[0197] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: Ring F consists of phenyl, pyridyl, pyrimidinyl, thiazolyl, pyridadinyl, oxazolyl, morpholinyl, [ka] Selected from TIFF0007898037000184.tif76164.

[0198] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R 1 These are independently hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 or -(CH2) n1 S(O)2R b5 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heteroaryl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R 1 These are independently hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 ,-(CH2) n1 S(O)2R b5 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heteroaryl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R 1 These are independently amino, oxo, and C. 1-3 Alkyl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 or -(CH2) n1 S(O)2R b5 Selected from, where the amino and C 1-3 Alkyl is cyano and C 1-3 It may be further substituted with alkyl.

[0199] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R 1 These are independently hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, -NS(O)R a1 R b1 ,-(CH2) n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 Selected from, where the amino acid, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heteroaryl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 1 These are independently amino, oxo, and C. 1-3 Alkyl, -NS(O)R a1 R b1 ,-(CH2)n1 S(O)NR a2 R b2 ,-P(O)R a3 R b3 , -NR a5 S(O)NR a4 R b4 ,-(CH2) n1 O(CH2) n2 R a5 ,-(CH2) n1 C(O)NR a6 R b6 ,-(CH2) n1 P(O)R a3 R b3 , [ka] ,-(CH2) n1 NR a8 C(O)R b8 Selected from, where the amino and C 1-3 Alkyl is cyano and C 1-3 It may be further substituted with alkyl.

[0200] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R 1 And the C atom bonded to it is linked to C 3-6 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Forms aryl or 5-10 member heteroaryl groups; Preferably, R 1 And the C atom bonded to it is further linked to C 3-4 It forms a cycloalkyl group.

[0201] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3Selected from haloalkyl groups; Preferably, R 4 , R 5 or R 6 Each of these is independently selected from fluoro or methyl.

[0202] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R 7 , R 8 , R 9 or R 10 These are, independently, hydrogen, deuterium, halogen, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated or C 1-3 Selected from alkyl halides; Preferably, R 7 , R 8 , R 9 or R 10 Each is independently selected from methyl.

[0203] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 or R b8 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and -NS(O)R a1 R b1 , C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 or R b8 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 A 3-8 membered heterocyclic structure containing 1-3 atoms selected from haloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-8 membered heteroaryls containing 1-3 atoms selected from N, O, or S; More preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 or R b8 Each of these elements is independently selected from hydrogen, deuterium, halogen, phenyl, or methyl.

[0204] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is as follows: R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , Ra4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 or R b8 These are, independently, hydrogen, deuterium, halogen, amino, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Selected from haloalkyl groups; Preferably, R a1 , R b1 , R a2 , R b2 , R a3 , R b3 , R a4 , R b4 , R a5 , R a6 , R b6 , R a7 , R b7 , R a8 or R b8 Each of these is independently selected from hydrogen, deuterium, halogen, and methyl.

[0205] In a further preferred embodiment of the present invention, the compound represented by general formula (XII) is further represented by general formula (XII-1): [ka] It is represented as follows.

[0206] The object of the present invention is the general formula (XVII): [ka] The objective is to provide a compound represented by, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt. Here, in the above formula, R 3 or R 13 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; L1, L2, or L3 are each independent, combined, C 2-4 Alkenylene, C 2-4 Alkynylene or -(CH2) n1 - Selected from; Ring B is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryls, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Selected from aryl or 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R 7 , R 8 , R 9 , R 10 , R 12 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 Aryl, 5-10 member heteroaryl, -(CH2) m1 Ure c1 Selected from, where the amino acid, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl, 5-10 member heteroaryl or -(CH2) m1 Ure c1 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10Selected from aryl, 5-10 member heteroaryl, where the amino, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 Aryl and 5-8 member heteroaryl compounds include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Alternatively, R 7 , R 8 , R 9 , R 10 , R 12 , R 14 or R 15It connects with the atom bonded to it and C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-12 Forms aryl or 5-12 member heteroaryl groups; or, R 7 and R 8 , R 14 and R 15 , R 10 and R 12 It connects with the atoms bonded to them and C 3-10 Cycloalkyl, 3-10 membered heterocyclic, C 6-12 They form aryl or 5-12 member heteroaryl compounds, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy, C 1-6 Deuterated haloalkoxy, C 2-6 Alkenil, C 2-6 Alkinyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-10 member heteroaryl groups; Ring E is C 3-14 Cycloalkyl, 3-14 member heterocyclyl, C 6-14 Selected from aryl or 5-14 member heteroaryl; Alternatively, ring E is, [ka] and; Ring C is C 3-12 Cycloalkyl, 3-12 membered heterocyclyl, C6-14 Selected from aryl or 5-14 member heteroaryls, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-6 Alkyl, C 1-6 Alkyl deuterated, C 1-6 Haloalkyl, C 1-6 Deuterated haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Sulfanyl, C 1-6 Deuterated sulfanyl, C 1-6 Alkoxy, C 1-6 Deuterated alkoxy, C 1-6 Haloalkoxy or C 1-6 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; n1, n2, or m1 are each independently selected from 0, 1, 2, 3, 4, or 5.

[0207] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R 3 or R 13 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-10 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 3 or R 13 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, methyl, or cyclopropyl, where the methyl or cyclopropyl is a halogen or C 1-3The alkyl group may be further substituted with one or more substituents.

[0208] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: Ring B is C 3-8 A 3-8 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 atoms selected from N, O, or S, where these are halogen, amino, oxo, thiol, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; Preferably, ring B is C 3-6 Selected from cycloalkyls, 3-6 membered heterocyclics containing 1-3 N, O, or S atoms, or 5-8 membered heteroaryls containing 1-3 N, O, or S atoms, where these are halogen, amino, oxo, thio, or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; More preferably, ring B is [ka] Selected from, where these are halogen, amino, oxo, thio or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0209] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R 4 , R 5 or R 6 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl or 5-8 membered heteroaryl, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl or 5-8 member heteroaryls include halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 4 , R 5 or R 6 Each is independently selected from fluorine, cyano, cyclopropyl, or methyl, where the cyclopropyl or methyl is a halogen, amino, oxo, thio, or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0210] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R 7 , R 8 , R 9 , R 10 , R 12 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Aryl, 5-8 member heteroaryl, -(CH2) m1 Ure c1 Selected from, where the amino acid, C 1-3 Alkyl, C1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl, 5-8 member heteroaryl, or -(CH2) m1 Ure c1 Deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 14 or R 15 These are, independently, hydrogen, deuterium, halogen, cyano, and C.2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 Selected from, where C 2-4 Alkinyl, C 3-6 Cycloalkyl, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl or -(CH2) m1 Ure c1 This may be further substituted with one or more substituents selected from deuterium, methyl deuterated, methyl, cyclopropyl, or oxo; More preferably, R 7 , R 8 , R 9 , R 10 , R 12 , R 14 or R 15 These are, independently, cyano, methyl, fluorine, cyclopropyl, ethynyl, or -(CH2) m1 Ure c1 Selected from, where methyl, cyclopropyl, ethynyl or -(CH2) m1 Ure c1 It may be further substituted with one or more substituents of deuterium, methyl deuterated, methyl, cyclopropyl, or oxo.

[0211] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R c1 These are hydrogen, deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C 6-10 Selected from aryl and 5-8 membered heteroaryls, where the amino, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 Aryl and 5-8 member heteroaryl compounds include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclyl, C6-10 may be further substituted with one or more substituents selected from aryl or 5- to 8-membered heteroaryl; Preferably, R c1 is selected from fluorine, methyl, cyano, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl or oxetane, wherein the methyl, difluoromethyl, trifluoromethyl, ethynyl, methylthio, amino, cyclopropyl or oxetane may be further substituted with one or more substituents of halogen, methoxy or deuterated methyl.

[0212] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVII) is as follows: R 7 、R 8 、R 9 、R 10 、R 12 、R 14 or R 15 each forms a 3- to 6-membered heterocyclic ring containing 1 to 3 atoms selected from C 3-6 cycloalkyl, N, O or S, C 6-10 aryl or 5- to 8-membered heteroaryl containing 1 to 3 atoms selected from N, O or S by linking with the atom to which it is attached; Preferably, R 7 、R 8 、R 9 、R 10 、R 12 、R 14 or R 15 each forms cyclopropyl by linking with the atom to which it is attached.

[0213] In a further preferred embodiment of the present invention, the compound represented by the general formula (XVII) is as follows: R 10 and R 12 form C 3-10 cycloalkyl, 3- to 10-membered heterocyclyl, C 6-12 aryl or 5- to 12-membered heteroaryl by linking with the atom to which it is attached; R10 and R 12 It connects with the atom bonded to it and C 3-6 A 3-6 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Forms a 5-8 membered heteroaryl compound containing aryl or 1-3 atoms selected from N, O, or S; Preferably, R 10 and R 12 It is linked to the atom it is bonded to. [ka] It forms.

[0214] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R 7 and R 8 , R 14 and R 15 , R 10 and R 12 It connects with the atoms bonded to them and C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10 They form aryl or 5-8 member heteroaryl compounds, where these are deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, thio, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy, C 1-3 Deuterated haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, C 6-10They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; Preferably, R 7 and R 8 , R 14 and R 15 , R 10 and R 12 It binds to the atoms that are bonded to them and forms cyclopropyl, [ka] These are formed, which may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, nitro, hydroxy, cyano, oxo, thio, methyl, or ethyl.

[0215] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: Ring E is C 3-8 A 3-10 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-10 membered heteroaryls containing 1-3 atoms selected from N, O, or S; Preferably, ring E is [ka] Selected from.

[0216] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: Ring E is, [ka] That is the case.

[0217] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: Ring C is C 3-8A 3-8 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, C 6-10 Selected from aryl or 5-8 membered heteroaryls containing 1-3 atoms selected from N, O, or S, where these are halogen, amino, nitro, hydroxyl, cyano, oxo, thiol, thio, C 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Deuterated haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Sulfanyl, C 1-3 Deuterated sulfanyl, C 1-3 Alkoxy, C 1-3 Deuterated alkoxy, C 1-3 Haloalkoxy or C 1-3 They may be further substituted with one or more substituents selected from deuterated haloalkoxys; Preferably, ring C is C 3-8 Selected from a 3-8 membered heterocyclic structure containing 1-3 atoms selected from cycloalkyl, N, O, or S, or a 5-8 membered heteroaryl structure containing 1-3 atoms selected from N, O, or S, where these are hydroxyl, thioxo, oxo, or C 1-3 They may be further substituted with one or more substituents selected from haloalkoxys; More preferably, ring C is [ka] These are selected from, where they may be further substituted with one or more substituents selected from hydroxyl, thio, or oxo.

[0218] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is as follows: R 13 C 1-6 Alkyl deuterated, C 1-6 Deuterated alkyl halides, C 1-6Deuterated hydroxyalkyl, C 1-6 Deuterated alkoxy, C 1-6 Deuterated haloalkoxy, C 3-8 Cycloalkyl, 3-8 member heterocyclic group, C 6-10 Aryl or 5-10 member heteroaryl, where the C 1-6 Deuterated alkyl, C 1-6 Deuterated haloalkyl, C 1-6 Deuterated hydroxyalkyl, C 1-6 Deuterated alkoxy, C 1-6 Deuterated haloalkoxy, C 3-8 Cycloalkyl, 3-8 member heterocyclic, C 6-10 Aryl or 5-10 member heteroaryl may be further substituted with one or more substituents selected from deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, C 1-6 Alkyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C[[ID=3D]] 2-6 Alkynyl, C 3-8 Cycloalkyl, 3-8 member heterocyclic group, C 6-10 Aryl or 5-10 member heteroaryl may be further substituted with one or more substituents selected therefrom; Preferably, R 13 is C 1-3 Deuterated alkyl, C 1-3 Deuterated haloalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Deuterated alkoxy, C 1-3 Deuterated haloalkoxy, C 3-6 Cycloalkyl, 3-6 member heterocyclic group, C 6-10 Aryl or 5-8 member heteroaryl, where the C 1-3 Deuterated alkyl, C 1-3 Deuterated haloalkyl, C 1-3 Deuterated hydroxyalkyl, C 1-3 Deuterated alkoxy, C 1-3Deuterated alkoxy halides, C 3-6 Cycloalkyl, 3-6 membered heterocyclic C 6-10 Aryl or 5-8 member heteroaryls include deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-3 Alkyl, C 1-3 Alkyl deuterated, C 1-3 Haloalkyl, C 1-3 Hydroxyalkyl, C 1-3 Alkoxy, C 1-3 Haloalkoxy, C 2-4 Alkenil, C 2-4 Alkinyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-10 They may be further substituted with one or more substituents selected from aryl or 5-8 membered heteroaryl groups; More preferably, R 13 is selected from -CD3 or cyclopropyl, where -CD3 or cyclopropyl is deuterium, halogen or C 1-3 They may be further substituted with one or more substituents selected from alkyl groups; More preferably, R 13 This is selected from cyclopropyl, where this is deuterium, halogen or C 1-3 It may be further substituted with one or more substituents selected from alkyl groups.

[0219] In a further preferred embodiment of the present invention, the compound represented by general formula (XVII) is further represented by general formula (XVII-1): [ka] It is represented as follows.

[0220] The present invention further includes general formulas (IN-A), (IN-B), or (IN-C): [ka] The present invention provides compounds represented by, their prodrugs, their stereoisomers, or pharmaceutically acceptable salts thereof. Here, In the general formula (IN-A), R 13 , Ring A, Ring B, L1, L2, R 4 , R 5 , R 6 and R 9 This is defined in the general formula (XIX); In the general formula (IN-B), ring C, ring D, ring E, L3, R 1 , R 7 , R 8 , R 14 , R 15 And n are as defined in general formula (XIX); In the general formula (IN-C), ring F, ring B, L1, L2, R 1 , R 4 , R 5 , R 6 , R 9 And x are as defined in general formula (XVI).

[0221] In a further preferred embodiment of the present invention, the compound represented by the general formula (IN-A) is as follows: R 13 C 3-8 Cycloalkyl, C 6-10 Selected from aryls, 5-10 member heteroaryls; the C 3-8 Cycloalkyl, C 6-10 Aryl, 5-10 member heteroaryls are composed of deuterium, halogen, amino, nitro, hydroxyl, cyano, oxo, and C. 1-6 It may be further substituted with one or more substituents selected from alkyl groups.

[0222] In a further preferred embodiment of the present invention, the compound represented by the general formula (IN-B) is as follows: Ring D is C 3-8 Selected from bicyclic cycloalkyl, 3-8 membered bicyclic heterocyclic, or 5-10 membered bicyclic heteroaryl containing 1-3 atoms selected from N, O, or S; preferably, ring D is C 3-6Selected from a bicyclic cycloalkyl, a 3-8 membered bicyclic heterocyclic containing 1-3 atoms selected from N, O, or S, or a 5-8 membered bicyclic heteroaryl containing 1-3 atoms selected from N, O, or S; preferably, ring D is [ka] Selected from.

[0223] In a further preferred embodiment of the present invention, the compound represented by the general formula (IN-C) is as follows: Ring F is selected from 8-14 membered tricyclic fused heterocyclic structures containing 1-5 heteroatoms.

[0224] The present invention also provides methods relating to the general formulas and compounds described above, wherein the methods are as follows: [ka] Includes, Here, Ring A, Ring B, Ring C, Ring D, Ring E, L1, L2, L3, R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 13 , R 14 , R 15 , R 16 This is defined in the general formula (XIX); General formula (IN-A) and general formula (IN-B) are reacted under the action of a condensing agent and a base to obtain general formula (XIX); The condensing agent is selected from EDC, DIC, DCC, TBTU, HATU5, HBTU, HCTU, DEPBT, PyBOP, or PyAOP; The aforementioned base is selected from DIPEA, DIEA, Et3N, NMP, DBU, or DABCO.

[0225] In a further preferred embodiment of the present invention, in the above preparation method, the condensing agent is selected from HATU; and the base is selected from DIPEA.

[0226] In a further preferred embodiment of the present invention, the preparation method is carried out under solvent conditions, the reaction solvent being selected from N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, acetonitrile, or dichloromethane; preferably, selected from N,N-dimethylformamide.

[0227] The present invention further provides a method for preparing the general formulas and compounds described above, wherein the method comprises the following steps: [ka] Includes, Here, Ring F, Ring B, Ring C, Ring E, L1, L2, L3, R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 ,R 10 , R 12 , R 13 , R 14 And x are as defined in general formula (XVI); General formula (IN-C) and general formula (IN-D) are reacted under the action of a condensing agent and a base to obtain general formula (XVI); The condensing agent is selected from EDC, DIC, DCC, TBTU, HATU, HBTU, HCTU, DEPBT, PyBOP, or PyAOP; preferably selected from HATU; The aforementioned base is selected from DIPEA, DIEA, Et3N, NMP, DBU, or DABCO.

[0228] In a further preferred embodiment of the present invention, in the above preparation method, the condensing agent is selected from HATU; and the base is selected from DIPEA.

[0229] In a further preferred embodiment of the present invention, the preparation method is carried out under solvent conditions, the reaction solvent being selected from N,N-dimethylformamide, N,N-dimethylacetamide, tetrahydrofuran, acetonitrile, or dichloromethane; preferably, selected from N,N-dimethylformamide.

[0230] The present invention also relates to a pharmaceutical composition comprising any compound represented by a general formula indicating a therapeutically effective dose, a prodrug thereof, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.

[0231] In certain embodiments of the present invention, the weight percentage (calculated as free base) of the compound, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt in the pharmaceutical composition is 0.1% to 95%, preferably 5% to 70%, for example, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%.

[0232] In certain embodiments of the present invention, the pharmaceutical composition is selected from tablets, capsules, liquids, or injections, and preferably further comprises a filler, optionally a disintegrant, or further comprises one or more flow promoters or lubricants.

[0233] In certain embodiments of the present invention, the pharmaceutical composition is either a rapid-release formulation or a sustained-release formulation.

[0234] In certain embodiments of the present invention, the unit dose of the drug composition, when calculated as free base, is 1 to 1000 mg, preferably 1 to 500 mg, or preferably 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg.

[0235] In certain embodiments of the present invention, the compound, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt can be administered by any convenient method, for example, orally, parenterally, orally, sublingually, intranasally, rectally, intrathecally, or transdermally, and the drug composition can be adjusted accordingly.

[0236] In certain embodiments of the present invention, the compound, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt can be formulated into liquid or solid formulations, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules, or lozenges.

[0237] The present invention also relates to the use of any of the compounds represented by the general formula shown, their prodrugs, their stereoisomers or pharmaceutically acceptable salts thereof, or the application of such pharmaceutical compositions in the preparation of GLP-1 receptor agonists.

[0238] The present invention also relates to the use of the compound represented by the general formula, its prodrug, its stereoisomer, or its pharmaceutically acceptable salt or its pharmaceutical composition in the preparation of a medicament for the treatment of a metabolic disorder (wherein the disorder is selected from diabetes mellitus, obesity or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes mellitus, obesity or non-alcoholic fatty liver disease).

[0239] The present invention also relates to a method for preparing pharmaceuticals for the treatment of metabolic diseases and related diseases using a compound represented by the general formula, a prodrug thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0240] The present invention also relates to methods for treating, preventing, and / or treating metabolic disorders, wherein the method comprises administering to a patient a therapeutically effective dose of a compound represented by the general formula, a prodrug thereof, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0241] The present invention further provides a method for treating a disease state using the compound or pharmaceutical composition of the present invention, wherein the disease state includes, but is not limited to, conditions related to GL...

Claims

1. Compounds of the following formula (I) or pharmaceutically acceptable salts thereof; 【Chemistry 1】

2. below 【Chemistry 2】 The compound according to claim 1.

3. The compound according to claim 1, which is a pharmaceutically acceptable salt of the following compound. 【Transformation 3】

4. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 2, A pharmaceutical composition containing the above.

5. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 3, A pharmaceutical composition containing the above.

6. A pharmaceutical composition for the treatment of metabolic disorders, comprising a therapeutically effective dose of the compound described in claim 1 or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition according to claim 6, wherein the metabolic disorder is selected from diabetes, obesity, or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes, obesity, or non-alcoholic fatty liver disease.

8. Compounds of the following formula (II) or pharmaceutically acceptable salts thereof; 【Chemistry 4】

9. below 【Transformation 5】 The compound according to claim 8.

10. The compound according to claim 8, which is a pharmaceutically acceptable salt of the following compound; 【Transformation 6】

11. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 9, A pharmaceutical composition containing the above.

12. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 10, A pharmaceutical composition containing the above.

13. A pharmaceutical composition for the treatment of metabolic disorders, comprising the compound described in claim 8 or a pharmaceutically acceptable salt thereof in a therapeutically effective dose.

14. The pharmaceutical composition according to claim 13, wherein the metabolic disorder is selected from diabetes, obesity, or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes, obesity, or non-alcoholic fatty liver disease.

15. Compounds of the following formula (III) or pharmaceutically acceptable salts thereof; 【Transformation 7】

16. below 【Transformation 8】 The compound according to claim 15.

17. The compound according to claim 15, which is a pharmaceutically acceptable salt of the following compound; 【Chemistry 9】

18. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 16, A pharmaceutical composition containing the above.

19. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 17, A pharmaceutical composition containing the above.

20. A pharmaceutical composition for the treatment of metabolic disorders, comprising the compound described in claim 15 as a therapeutically effective dose or a pharmaceutically acceptable salt thereof.

21. The pharmaceutical composition according to claim 20, wherein the metabolic disorder is selected from diabetes mellitus, obesity, or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes mellitus, obesity, or non-alcoholic fatty liver disease.

22. Compounds of the following formula (IV) or pharmaceutically acceptable salts thereof; 【Chemistry 10】

23. below 【Chemistry 11】 The compound according to claim 22.

24. The compound according to claim 22, which is a pharmaceutically acceptable salt of the following compound; 【Chemistry 12】

25. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 23, A pharmaceutical composition containing the above.

26. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 24, A pharmaceutical composition containing the above.

27. A pharmaceutical composition for the treatment of metabolic disorders, comprising the compound described in claim 22 as a therapeutically effective dose or a pharmaceutically acceptable salt thereof.

28. The pharmaceutical composition according to claim 27, wherein the metabolic disorder is selected from diabetes, obesity, or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes, obesity, or non-alcoholic fatty liver disease.

29. Compounds of the following formula (V) or pharmaceutically acceptable salts thereof; 【Chemistry 13】

30. below 【Chemistry 14】 The compound according to claim 29.

31. The compound according to claim 29, which is a pharmaceutically acceptable salt of the following compound; 【Chemistry 15】

32. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 30, A pharmaceutical composition containing the above.

33. (i) a pharmaceutically acceptable carrier, and (ii) The compound according to claim 31, A pharmaceutical composition containing the above.

34. A pharmaceutical composition for the treatment of metabolic disorders, comprising the compound described in claim 29 as a therapeutically effective dose or a pharmaceutically acceptable salt thereof.

35. The pharmaceutical composition according to claim 34, wherein the metabolic disorder is selected from diabetes, obesity, or non-alcoholic fatty liver disease-related disorders, or other related disorders resulting from diabetes, obesity, or non-alcoholic fatty liver disease.

Images